| UHC Commercial Medical & Drug | Provider Administered Drugs – Site of Care – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Respiratory Pathogen Nucleic Acid Detection Testing – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Rhinoplasty and Other Nasal Procedures – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Rituximab (Riabni®, Rituxan®, Ruxience®, & Truxima®) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Roctavian® (Valoctocogene Roxaparvovec-Rvox) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sacral Nerve Stimulation for Urinary and Fecal Indications – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sacroiliac Joint Interventions – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sensory Integration Therapy and Auditory Integration Training – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sinus Surgeries and Interventions – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sleep Studies – Commercial and Individual Exchange Medical Policy | 2026-01-01 |